Education
About Us
Working with TipRanks
Follow Us
Metavia Inc. (MTVA)
:MTVA
MTVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.56 - $4.32
Previous CloseN/A
Volume36.62K
Average Volume (3M)136.79K
Market Cap
$11.75M
Enterprise Value$4.73M
Total Cash (Recent Filing)$16.02M
Total Debt (Recent Filing)$136.00K
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 19, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding19,589,132
10 Day Avg. Volume290,536
30 Day Avg. Volume136,788
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-526.10
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$3.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial OutlookThe company expects to have financial runway into 2026, following recent equity financing.
Safety ProfileDA-1726 did not exhibit any clinically significant increases in heart rate or QTcF intervals up to a dose of 32mg, highlighting its favorable cardiovascular safety profile.
Treatment EfficacyDA-1726 has shown initial weight loss and positive safety results with no plateau effect in its ongoing study.
Bears Say
Market CompetitionShares of MTVA are under pressure, down ~20%, stemming from a combination of misunderstanding of the data itself and activity in the obesity/metabolic space from Merck which is also pressuring Viking shares.
Stock PerformanceMTVA shares were down 56% on the news, which is viewed as an overreaction on what was only an early-stage study.
MetaVia News
MTVA FAQ
What was Metavia Inc.’s price range in the past 12 months?
Metavia Inc. lowest stock price was $0.56 and its highest was $4.32 in the past 12 months.
What is Metavia Inc.’s market cap?
Metavia Inc.’s market cap is $11.75M.
When is Metavia Inc.’s upcoming earnings report date?
Metavia Inc.’s upcoming earnings report date is Aug 19, 2025 which is in 12 days.
How were Metavia Inc.’s earnings last quarter?
Metavia Inc. released its earnings results on May 14, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.03.
Is Metavia Inc. overvalued?
According to Wall Street analysts Metavia Inc.’s price is currently Undervalued.
Does Metavia Inc. pay dividends?
Metavia Inc. does not currently pay dividends.
What is Metavia Inc.’s EPS estimate?
Metavia Inc.’s EPS estimate is -0.22.
How many shares outstanding does Metavia Inc. have?
Metavia Inc. has 19,589,132 shares outstanding.
What happened to Metavia Inc.’s price movement after its last earnings report?
Metavia Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went up 1.493%.
Which hedge fund is a major shareholder of Metavia Inc.?
Currently, no hedge funds are holding shares in MTVA
Company Description
Metavia Inc.
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
MTVA Stock 12 Month Forecast
Average Price Target
$3.00
▲(400.00% Upside)
Technical Analysis
Palatin Technologies
―
Evogene
―
TransCode Therapeutics
―
Silexion Therapeutics
―
Apollomics
―
Ownership Overview
52.89% Insiders
0.50% Mutual Funds
2.68% Other Institutional Investors
43.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---